RHY 0.00% 5.6¢ rhythm biosciences limited

Lack of communication

  1. 17 Posts.
    lightbulb Created with Sketch. 2
    Several red flags here. Studies and reagent development due for completion in 2019. I realise it's out of their control now, but clinical trial recruitment could be suspended indefinitely. And yet - still no communication from the company. This is extremely poor management. For those who have corresponded with the CEO, has there been any explanation why they are refusing to update the market ?
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.